TSUMURA & CO. Logo

TSUMURA & CO.

A leader in Japanese Kampo herbal medicine, producing prescription and OTC formulations.

4540 | T

Overview

Corporate Details

ISIN(s):
JP3535800001
LEI:
Country:
Japan
Address:
港区赤坂二丁目17番11号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Founded in 1893, Tsumura & Co. is a leading Japanese pharmaceutical company specializing in Kampo medicine, a traditional Japanese herbal therapy. The company's primary business is the manufacture and sale of prescription and over-the-counter (OTC) Kampo formulations, which are derived from natural substances. Its product portfolio also includes other medications and consumer items such as herbal bath salts. Tsumura manages an integrated value chain, from the procurement of raw medicinal herbs to the production of finished goods. The company is guided by a philosophy of achieving “Cho-WA” (harmony) between mind and body, blending tradition with scientific innovation to contribute to individual and societal well-being.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-11 08:16
Interim Report
確認書
Japanese 8.9 KB
2025-11-11 08:14
Interim Report
半期報告書-第90期(2025/04/01-2026/03/31)
Japanese 267.3 KB
2025-09-10 07:55
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 22.6 KB
2025-08-05 07:44
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 22.6 KB
2025-07-08 07:37
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 22.7 KB
2025-07-01 09:20
Post-Annual General Meeting Information
臨時報告書
Japanese 27.7 KB
2025-06-24 06:22
Governance Information
内部統制報告書-第89期(2024/04/01-2025/03/31)
Japanese 25.7 KB
2025-06-24 06:21
Annual Report
有価証券報告書-第89期(2024/04/01-2025/03/31)
Japanese 3.5 MB
2025-06-24 06:21
Registration Form
確認書
Japanese 8.9 KB
2025-06-11 06:35
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 27.8 KB
2025-05-12 07:16
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 28.0 KB
2025-04-07 07:10
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 24.9 KB
2025-03-10 07:05
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 22.1 KB
2025-03-03 08:27
Share Issue/Capital Change
訂正臨時報告書
Japanese 30.2 KB
2025-02-20 07:30
Share Issue/Capital Change
臨時報告書
Japanese 27.8 KB

Automate Your Workflow. Get a real-time feed of all TSUMURA & CO. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for TSUMURA & CO.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for TSUMURA & CO. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Poltreg S.A. Logo
Pioneering T-regulatory cell therapies for autoimmune diseases like diabetes, MS, and ALS.
Poland
PTG
PolyPeptide Group AG Logo
A global CDMO specializing in peptide and oligonucleotide APIs for pharma and biotech partners.
Switzerland
PPGN
PolyPid Ltd. Logo
Develops localized, prolonged-release drug therapies for surgery, oncology & metabolic diseases.
United States of America
PYPD
Praxis Precision Medicines, Inc. Logo
Developing therapies for CNS disorders using insights from genetic epilepsies.
United States of America
PRAX
PRECIGEN, INC. Logo
Develops gene and cell therapies for difficult-to-treat diseases using precision technology.
United States of America
PGEN
Precipio, Inc. Logo
Provides blood cancer diagnostic services & products to improve accuracy for physicians & labs.
United States of America
PRPO
PRECISION BIOSCIENCES INC Logo
A clinical-stage company using ARCUS gene editing to treat cancer and rare genetic diseases.
United States of America
DTIL
Develops sensitive point-of-care biomarker diagnostics for human and animal health.
South Korea
335810
Prelude Therapeutics Inc Logo
Clinical-stage oncology company developing novel protein degraders and ADCs for cancer.
United States of America
PRLD
A global CDEMO offering end-to-end solutions for antibody therapeutics and biologics.
South Korea
334970

Talk to a Data Expert

Have a question? We'll get back to you promptly.